EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITION AND NON-SMALL CELL LUNG CANCER
The majority of non-small cell (NSC) lung cancers express epidermal growth factor receptor (EGFR). Many studies have evaluated the clinical effect from targeted therapy achieved by blocking EGFR in patients with NSC lung cancer. Treatment of biologically unselected patients with NSC lung cancer
Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer: a pilot experience.
Computed tomography (CT)-based treatment planning has been widely accepted as the method of choice for radiation therapy of lung cancers. (1) With advances in planning technology and treatment delivery systems, radiation oncologists are now able to deliver radiation to a very precise target with
The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases
Non-small cell lung cancer is characterized by a specific metastatic pattern. The mechanism for organ-specific metastasis is poorly understood, although evidence has suggested that the chemokine stromal derived factor-1 (CXCL12) and its cognate receptor CXCR4 may regulate breast cancer metastasis.
Lung Cancer, Non-Small Cell
Lung cancer, non-small cell Definition Non-small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. Primary lung cancer starts in the lung itself, and is divided into small
Non-small cell lung cancer: new hope for a chronic illness.
Since the 1980s, important advances have been made in the treatment of non-small cell lung cancer (NSCLC).The advances have doubled the cure rate, allowing more patients with NSCLC to live longer with improved quality of life. Since the 1980s, studies using conventional chemotherapy have shown that
Survival after Surgery in Stage IA and IB Non-Small Cell Lung Cancer
Rationale: Whether histologic subtype of non-small cell lung cancer (NSCLC) has an important effect on prognosis after surgery is unknown. Objectives: We hypothesized that we could predict mortality more effectively by integrating precise tumor size and histology rather than relying on conventional
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Lung cancer Is the leading cause of cancer-related mortality not only In the United States but also around the world. In North America, lung cancer has become more predominant among former than current smokers. Yet in some countries, such as China, which has experienced a dramatic Increase In the
Endoscopic Ultrasound in Non-Small Cell Lung Cancer and Negative Mediastinum on Computed Tomography
Despite technical advances in staging non-small cell lung cancer (NSCLC), accurate staging remains a challenge. Endoscopic ultrasound is useful in staging NSCLC when lymphadenopathy is present on a computed tomography (CT), but its role in the absence of lymphadenopathy on CT has not been well
Chemotherapy in the treatment of non-small cell lung cancer.
Lung cancer is currently the leading cause of cancer death in both men and women in the United States and accounts for approximately 150,000 deaths per year.[1] For purposes of treatment planning, several histologies, including squamous cell carcinoma, adenocarcinoma and large cell carcinoma, as
Quantification of ^sup 18^F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker?
Non-small cell lung cancer (NSCLC) is a heterogeneous group of carcinomas with a similar cellular and molecular origin hut different biologic behaviors and prognoses. Accurate staging is essential for estimating prognosis and choosing the best combination of treatment modalities such as surgery,
